Attenuated Vaccinia Virus E3L Deletion for Cancer Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunotherapy approaches for cancer, particularly in melanoma, have limited success due to immune evasion mechanisms employed by tumors, and existing oncolytic viruses like wild-type vaccinia can be immunosuppressive, hindering effective anti-tumor immune responses.
Innovation Solution
Development of a replication-competent but attenuated vaccinia virus strain (E3LΔ83N-TK−) with deletion of the Z-DNA-binding domain and thymidine kinase, expressing human Flt3L or GM-CSF, which is used intratumorally alone or in combination with immune checkpoint blocking agents to stimulate immune responses and enhance anti-tumor immunity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If wild-type vaccinia virus is used as oncolytic therapy, then tumor cell lysis and immunotherapy effect are achieved, but immune suppression and reduced anti-tumor immunity occur
Solution Approach 1:
The patent extracts and removes the Z-DNA binding domain from the vaccinia virus E3L gene, creating a deletion mutant (E3LΔ83N) that loses the ability to suppress host immune responses. This extraction eliminates the harmful immunosuppressive function while preserving the oncolytic activity, thereby resolving the contradiction between tumor cell lysis and immune suppression.
Solution Approach 2:
The patent modifies the viral genome by deleting specific amino acid residues (83-93) from the E3L protein, changing its structural and functional parameters. This parameter change transforms the virus from an immunosuppressive wild-type strain to an attenuated strain that is 1000-fold less virulent but maintains oncolytic capability and enhances anti-tumor immunity.
2Object-generated harmful factors
If attenuated vaccinia virus with E3L deletion is used, then immune suppression is reduced and anti-tumor immunity is enhanced, but viral replication competence is compromised
Solution Approach 1:
The patent applies local quality modification by deleting the Z-DNA binding domain specifically from the E3L gene while maintaining other viral genes intact. This localized deletion reduces immunosuppression without compromising essential replication functions, allowing the virus to maintain replication competence while becoming less pathogenic and more immunostimulatory.
3Reliability
If combination therapy with immune checkpoint blocking agents is used, then tumor eradication and survival are significantly improved, but treatment complexity and cost increase
Solution Approach 1:
The patent merges the attenuated vaccinia virus therapy with immune checkpoint blocking agents in a combination treatment regimen. The viral vector delivers immunostimulatory cytokines (GM-CSF, Flt3L, IL-12) that synergize with checkpoint inhibitors to enhance anti-tumor immunity. This combination achieves superior tumor eradication and survival outcomes compared to monotherapy, addressing the contradiction between treatment efficacy and regimen complexity.
Data Source
AI summary
The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK−) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.